1	Eliminating mother-to-child transmission of HIV in
2	Tanzania calls for efforts to address factors associated
3	with a low confirmatory test
4	
5	
6	
7	Baraka M. Morris <sup>1*</sup> , Mukome Nyamhagata <sup>2</sup> , Edith Tarimo <sup>1</sup> , Bruno Sunguya <sup>1</sup>
8	
9	<sup>1</sup> Muhimbili University of Health and Allied Sciences, P.O. Box 65001, Dar es salaam,
10	Tanzania
11	<sup>2</sup> Ministry of Health, P.O. Box 743, Dodoma, Tanzania
12	
13	*Corresponding author
14	Email: <u>bamalaki@yahoo.com</u> (BMM)
15	
16	
17	
18	
19	

# 20 Abstract

21 **Background:** Option B+ approach for prevention of mother-to-child transmission 22 (PMTCT) has demonstrated the potential to eliminate pediatric HIV infections. Its success 23 depends on early infant diagnosis (EID) of HIV among the exposed infants within the first 6 weeks, and a subsequent confirmatory HIV test at the 18<sup>th</sup> month. However, most mothers 24 25 enrolled in the PMTCT-option B+ cascade of services in Tanzania do not turn-up for such 26 confirmatory tests. We examined factors associated with the turning-up of mother-baby 27 pairs on the PMTCT program for confirmatory HIV testing 18 months post-delivery in 28 Tanzania.

Methods: This study utilized longitudinal data collected between 2015 and 2017 from 751 mother-baby pairs enrolled in the PMTCT- Option B+ approach in 79 health facilities from the 12 regions of Tanzania-mainland. Analysis was conducted using descriptive statistics to characterize the proportion of mother-baby pairs turning up for a confirmatory test and logistic regression analysis to examine factors associated with turning up for a confirmatory HIV testing at the 18<sup>th</sup> month.

35 Results: A total of 751 mother-baby records were observed only and 44.2% (95% CI: 40.7 36 -47.8) of them received the HIV confirmatory test at 18 months. Mothers aged 25 years 37 or above (adults' mothers) were 1.44 more likely to turn up for confirmatory HIV-testing 38 than young mothers; mothers with partners tested for HIV were 1.74 more likely to have 39 confirmatory HIV-testing compared with partners not tested for HIV; newly HIV-positive 40 mothers diagnosed on enrolment were 28% less likely to turn up their babies for 41 confirmatory HIV-testing compared to known HIV-positive mothers; mothers with 42 treatment supporters were 1.58 more likely to receive confirmatory HIV-testing compared

to mothers without one, and mothers with babies whose DBS-PCR-1 was collected were
3.61 more likely to have confirmatory HIV-testing than those who didn't collect DBSPCR-1.

46 Conclusion: This study reveals that the turn-up for confirmatory HIV testing at 18 months 47 among mother-baby pairs enrolled in the Option B+ approach is still low in Tanzania. This 48 turn-up is associated with low maternal age, having a male partner who has not tested for 49 HIV, lack of experience with HIV services, lack of treatment supporters, and failure to take 50 the first DBS-PCR HIV test within the first two months post-delivery.

51

# 52 Introduction

53 The overall risk of HIV transmission from mother-to-child without any intervention ranges 54 from 20% to 45% (Ref). Such unprecedented risk can be ameliorated with a successful 55 implementation of preventing mother-to-child transmission (PMTCT) interventions that 56 includes screening and treatment of both mothers and their newborn. [1-3] Remarkable 57 efforts have been made in scaling up PMTCT services globally. Such efforts have resulted 58 in marked improvement in PMTCT among countries with a heavy burden of HIV/AIDS.[4] 59 Nevertheless, despite marked efforts and investment, the unprecedented burden of new 60 infections still occurs among HIV-exposed newborns globally-Tanzania is no exception. 61 The World Health Organization (WHO) recommended the adoption of universal 62 antiretroviral treatment or Option B+, as the preferred PMTCT approach in LMICs with 63 high HIV prevalence, high fertility, and extended breastfeeding. [2, 5] Under this plan, all 64 women who test HIV positive are enrolled in lifelong ART soon after HIV diagnosis,

regardless of their CD4 count, or HIV clinical stage. The implementation of the Option B+ program requires women and their infants to access HIV care including a PMTCT cascade of HIV prevention services for two years post-delivery.[6] The Option B+ cascade of interventions requires the exposed children to undertake a confirmatory HIV test at 18 months of age to determine whether they are infected. If the child is infected, both the mother and her child are transferred to Care Treatment Clinics (CTC).[5-7]

71

72

73 The adoption and implementation of Option B+ in Tanzania still face several challenges 74 similar to many other sub-Saharan countries. Studies reveal that a significant proportion of 75 women decline the PMTCT service outright, while another group silently defaults from care.[8, 9] The proportion of infants who receive confirmatory HIV tests is also very low. 76 77 Only 34.6% of babies from HIV-infected mothers are brought for confirmatory HIV testing at 18 months of age.[10] Low turn-up for confirmatory HIV testing denies the opportunity 78 79 for early diagnosis and treatment among children who might have been infected during 80 breastfeeding. Findings show that most of these undiagnosed children are likely to die 81 before their second birthday if they do not receive treatment. [2, 7, 11]

82

Evidence on the reasons and causes for low turn-up for confirmatory tests remains inconclusive and varies in Tanzania like in other countries. Thus, this study investigated factors associated with poor turn-up for confirmatory HIV testing at 18 months of age among mother-baby pairs enrolled in the PMTCT Option B+ cascade in Tanzania.

87

# 88 Materials and Methods

### 89 Study Design and Population

90 This secondary analysis study used data from a cohort of mother-baby pairs who received 91 PMTCT care in 79 health facilities in 12 selected regions of Tanzania between 2015-2017. 92 Tanzania approved the National Guidelines for the implementation of Option B+ in 93 2013. According to this guideline, all pregnant mothers who tested HIV positive were 94 counseled and enrolled in the Option B+ approach where they were monitored from their 95 first antenatal clinic visit until their babies were two years old.[12, 13] Data was collected 96 to monitor and evaluate the adherence to treatment among mother-baby pairs enrolled in 97 the Option B + approach of PMTCT.

98

99 Sample Size and sampling

Multistage random sampling was used to select 79 health facilities in the 12 regions
of Tanzania mainland for the primary study. In these health facilities, a total of 4,738
HIV-positive mother-baby pairs were enrolled in the Option B+ program from 2015
to 2017. In the current study, only 751 HIV-positive mother-baby pairs were analyzed
owing to the completeness of their medical records.

105

## 106 Variables and measures

The outcome variable was the infant's confirmed HIV status at the 18<sup>th</sup> month of age. The
outcome responses were categorical and measured using a nominal scale (dichotomous -

Yes/No), where "Yes" was for mother-baby pairs who turned for confirmatory HIV testing
and "No" was for mother-baby pairs who did not turn for confirmatory HIV testing (Lost
to Follow up). This did not include babies who died in the course of 18 months.

112 Independent variables included eight variables. These are: Maternal age groups defined 113 based on the WHO age groups where mothers aged 24 years and less form the young group 114 and those aged 25 years and above from the adult group (2) Gravidity defined as the number 115 of times that a woman has been pregnant. Gravidity was classified into two categories, the 116 first category for mothers in their first & second pregnancies (G1-G2) and the second 117 category for mothers with more than two pregnancies (G3 - max). (3) Gestational age is 118 the measure (usually in weeks) of the age of a pregnancy. Normally, the gestation age is 119 grouped into three groups (trimesters). However, the WHO recommends women start 120 antenatal care in their first trimester. In this study, the gestation age was grouped into two 121 categories, the first category for mothers who were enrolled in their 1<sup>st</sup> trimesters and the 122 second category for mothers who enrolled in the 2<sup>nd</sup> and 3<sup>rd</sup> trimesters. (4) Live with Partner 123 (marital status) measured as a nominal categorical (dichotomous -Yes/No) variable where 124 "Yes" was for married and cohabited mothers and "No" was for Single, divorced, and 125 widowed mothers. (5) Partner tested measured as a categorical variable using a nominal 126 scale (dichotomous -Yes/No), where "Yes" was for mothers with a partner who has tested 127 for HIV and "No" for mothers with a partner who has not tested for HIV (6) Maternal HIV 128 status at enrolment measured as a nominal categorical variable with two groups. The first 129 group was for mothers whose HIV status was already known as HIV positive and the 130 second group was for mothers who were newly diagnosed as HIV positive at enrollment in 131 antenatal care (Known HIV +ve and New HIV +ve). (7) Presence of treatment supporters

was measured dichotomously using a nominal scale. "Yes" was for mothers with treatment supporter(s) and "No" was for mothers without treatment supporter(s). (8) Lastly, Collection of the first dry blood smear (DBS-PCR-1) within the first two months postdelivery. Option B+ PMTCT cascade requires HIV-exposed infants to have their first HIV test within 2 months of age for early HIV diagnosis. For each mother-baby pair it was recorded whether DBS-PCR-1 was collected or not and hence, was measured dichotomously (Yes/No) using a nominal scale.

139 **Loss to Follow-up** 

140 Loss to follow-up was one of the child's final status at the last visit. Likewise, this was one 141 of the observations for not showing up for confirmatory HIV testing at the 18<sup>th</sup> month age 142 of the baby. However, in this study, we did not analyze the child's last status, because child 143 status is determined at the end of two years.

144

#### 145 **Data Analysis**

146 The analysis focused on examining the upshots of Option B+ on the compliance to services 147 among mother-baby pairs enrolled in the PMTCT program in Tanzania mainland. Factors 148 associated with poor turn-up for confirmatory HIV testing at 18 months of infant age 149 among these mother-baby pairs were analyzed as well. These factors were placed into four 150 groups namely: maternal social-demographic characteristics (maternal age, gravidity, 151 gestation age at enrolment, and live with a partner), experience with HIV services on 152 enrolment (maternal HIV status), partner involvement on turn-up for confirmatory HIV 153 testing (Partner tested), and presence of treatment supporters (treatment supporter). The

analysis examined whether these factors were associated with turn-up for confirmatoryHIV testing.

156 Data were cleaned and analyzed using the STATA version 15<sup>th</sup> software package. 157 Measures of central tendency (frequencies, means, medians, and standard deviations) 158 described the socio-demographic characteristics of study participants (HIV-positive 159 mother-baby pairs). A chi-square test of independence was used for the bivariate analysis 160 of the relationships between outcomes and independent categorical variables. A p-value of 161 0.05 or less was used to determine the significance of the association between predictors 162 and outcome variables. Then the multivariate analysis using multinomial logistic 163 regression analysis was used to determine associations and ascertain the effect of 164 confounders. The backward elimination method was used to determine the final model. 165 First, the model contained all variables that showed significant association with the 166 outcome variable during the bivariate analysis. The least significant variable (the one with 167 the highest p-value) was removed from the model. The elimination continued until the 168 stopping rule was reached. The stopping rule was when all remaining variables had a 169 significant p-value (P=0.05).

#### 170 Ethical Consideration

Ethical clearance for the PMTCT project was obtained from the National Institution of
Medical Research (NIMR) and the permission to use mother-baby pairs PMTCT Option
B+ cascade data was received from the Ministry of Health, Community Development,
Gender, Elderly, and Children, through the PMTCT coordination unit. Informed consent
was waived because this was purely secondary data and hence, we did not interact with the

- subjects. Confidentiality of participants in the data was highly maintained and special
- 177 identification numbers were used to ensure anonymity.

178

- 179
- 180 **Results**

#### **181** General characteristics

182 The mean age of mothers included in this analysis was 28.9 (SD = 5.8) years. The mean

183 number of pregnancies (gravidity) was 3±2 and the mean gestation age at enrolment was

184 19.1±6.2 weeks. A total of 502 (78.9%) of 636 mothers who indicated their marital status
185 were living with their partners (i.e. married or cohabited).

186

#### 187 Baseline HIV Testing Characteristics of Mother-Baby Pairs

188 Of the 751 mother-baby records observed, 733 (97.6%, 95% CI: 96.2 – 98.5) had DBS1

189 collected by 2 months of age but only 332 (44.2%, 95% CI: 40.7 - 47.8) mother-baby pairs

received the HIV confirmatory test at 18 months. More than half of 429 (57.1%, 95% CI:

191 53.5 – 60.6) mothers were newly HIV positive and diagnosed upon enrolment; less than a

quarter of 157 (20.9%, 95% CI: 18.1 - 24) mothers had tested partners; and the majority

193 644 (85.5%, 95% CI: 83.1 – 88.1) of mothers had treatment supporters. (Table 1)

194

A chi-square test of independence was used to assess the relationship between independent
variables and mother-baby pairs HIV confirmatory testing at the18 months of age

197	(confirmed HIV testing). There was a significant relationship between the following
198	variables and confirmed HIV testing: maternal age group $X^2(1, N = 751) = 6.57, p = 0.01;$
199	gravidity $X^2(1, N = 751) = 6.96$ , p = 0.008; maternal HIV status at enrollment $X^2(1, N =$
200	751) = 4.73, p = 0.03; partner being tested $X^2(1, N = 751) = 7.94$ , p = 0.005; collection
201	dried blood spot for <i>HIV</i> -1 PCR tested $X^2(1, N = 751) = 5.67$ , p = 0.02; and presence of
202	treatment supporter tested $X^2(1, N = 751) = 4.69$ , p = 0.03. There was not a significant
203	relationship between the following variables and confirmed HIV testing: gestation age
204	group at enrolment $X^2(1, N = 751) = 3.60$ , p = 0.06 and marital status (Live with a partner)
205	$X^{2}(1, N = 636) = 0.06, p = 0.81$ . Table 1 below summarizes the results of the descriptive
206	analysis of the baseline HIV testing characteristics of mother-baby pairs
207	Table 1: The Baseline HIV Testing Characteristics of the 751 Mother-Baby Pairs

208 enrolled in the PMTCT cascade in selected health facilities between 2015 and 2017

Va		E	050/ Conf Inton	Confirmed H	D V - L	
Va	riables	Frequency (%)	95% Conf. Interv	No (%)	Yes (%)	P-Value
Maternal	Young (10 – 24)	188 (25)	22.1 - 28.2	120 (63.8)	68 (36.2)	0.010
Age Group	Adults (25 – max)	563 (75)	71.7 – 77.9	299 (53.2)	264 (46.9)	
	Total	751 (100)		419 (55.8)	332 (44.2)	
Gravidity	G1 – G2	286 (38.1)	34.7 - 41.6	177 (61.9)	109 (38.1)	0.008
Groups	G3 - Max	465 (61.9)	58.4 - 65.3	242 (52.0)	223 (48.0)	
	Total	751 (100)		419 (55.8)	332 (44.2)	
Gestation	1 <sup>st</sup> Trimester	138 (18.4)	15.8 - 21.3	87 (63.0)	51 (37.0)	0.058
Age Group	2 <sup>nd</sup> & 3 <sup>rd</sup> Trimester	613 (81.6)	78.7 - 84.2	332 (54.2)	281 (45.8)	
	Total	751 (100)		419 (55.8)	332 (44.2)	
Live with	No	134 (21.1)	18.1 - 24.4	76 (56.7)	58 (43.3)	0.814
Partner	Yes	502 (78.9)	75.6 - 81.9	279 (55.6)	223 (44.4)	
	Total	636 (100)		355 (55.8)	281 (44.2)	
Maternal HIV	Know HIV +ve	322 (42.9)	39.4 - 46.5	165 (51.2)	157 (48.8)	0.030
status on	New HIV +ve	429 (57.1)	53.5 - 60.6	254 (59.2)	175 (40.8)	
Enrolment	Total	751 (100)		419 (55.8)	332 (44.2)	
Partner	No	594 (79.1)	76-81.8	347 (58.4)	247 (41.6)	0.005
Tested	Yes	157 (20.9)	18.1 - 24	72 (45.9)	85 (54.1)	
	Total	751 (100)		419 (55.8)	332 (44.2)	
DBS1	No	18 (2.4)	1.5 - 3.8	15 (83.3)	3 (16.7)	0.017
Collected	Yes	733 (97.6)	96.2 - 98.5	404 (55.1)	329 (44.9)	
	Total	751 (100)		419 (55.8)	332 (44.2)	
Treatment	No	107 (14.3)	11.9 – 16.9	70 (65.4)	37 (34.6)	0.030
Supporter	Yes	644 (85.7)	83.1 - 88.1	349 (54.2)	295 (45.8)	
	Total	751 (100)		419 (55.8)	332 (44.2)	

Confirmed	No	419 (55.8)	52.2 - 59.3		
HIV	Yes	332 (44.2)	40.7 - 47.8		
Testing	Total	751 (100)			

209

210

### 211 Factors associated with confirmatory HIV testing among

#### exposed children at 18 months of age

All factors that were statistically significantly associated with the dependent variable were entered into the regression analysis. The binary logistic regression was conducted to provide unadjusted odds ratios. Then multivariate logistic regression was used to obtain an adjusted odds ratio (OR). During the backward elimination method to determine the final model, gravidity and gestation age were not statistically significant and were eliminated consecutively (Table 2).

219 The results of multiple regression analysis of the factors included in the final model were: 220 Maternal age group adults' mothers were 1.44 more likely to receive confirmatory HIV-221 testing for their babies than young mothers (Maternal age group AOR=1.44 and p = 0.04). 222 Mothers with partners who tested for HIV were 1.74 more times likely to have 223 confirmatory HIV testing than those with partners not tested for HIV (Partner tested 224 AOR=1.74 and p=0.003). New HIV-positive mothers diagnosed on enrolment were 0.72 225 less likely to turn up their babies for confirmatory HIV-testing than known HIV-positive 226 mothers (Maternal HIV status at enrolment AOR=0.72 and p=0.033); mothers with 227 treatment supporters were 1.58 times more likely to receive confirmatory HIV-testing than 228 mothers without treatment supporters (Treatment supporter AOR=1.58 and p=0.041), and

- finally, mothers with babies whose DBS1 was collected were 3.61 more likely to have
- 230 confirmatory HIV-testing (DBS1 collection AOR=3.61 and p=0.048).
- 231
- 232 Table 2: Logistic regression analysis of factors associated with turn up for
- 233 confirmatory among HIV-positive mother-baby pairs who were enrolled in PMTCT
- cascade in selected health facilities between 2015 and 2017.

Factor	OR	P-Value	95% CI	AOR	P-Value	95% CI
Maternal Age Group	1.56	0.011	1.11 – 2.19	1.44	0.040	1.02 - 2.04
Partner tested	1.66	0.005	1.16 - 2.36	1.74	0.003	1.21 - 2.50
Maternal HIV Status	0.72	0.030	0.54 - 0.97	0.72	0.033	0.53 - 0.97
Treatment Supporter	1.60	0.031	1.04 - 2.45	1.58	0.041	1.02 - 2.46
DBS1 Collected	4.07	0.027	1.17 – 14.18	3.61	0.048	1.01 – 12.84

235

236

# 237 **Discussion**

238 This study provides a picture of the implementation of Option B+ in Tanzania mainly 239 focusing on early infant diagnosis (EID) of HIV among exposed infants. Confirmatory HIV 240 testing is a very important part of EID to ensure that all affected infants are identified and 241 enrolled in treatment. In this study 44.2% of mothers enrolled in Option B+ turned in their 242 babies for confirmatory testing. The study revealed that: Maternal age - adult mothers were 243 more likely to take their babies for confirmatory HIV testing than young mothers, mothers 244 with a tested partner were more likely to take their babies for confirmatory HIV testing 245 than mothers with partners who have not been tested, newly diagnosed mothers were less

likely to take their babies for confirmatory HIV testing than mothers who knew of their
HIV status prior to the enrolment (Known HIV positive), mothers with treatment
supporters were more likely to take their babies for confirmatory HIV testing than mothers
without treatment supporters, and mothers who brought their babies for DBS-PCR-1
collection were more like to take for confirmatory HIV test at the 18-month post-delivery
than those mothers who did not bring their babies for DBS-PCR-1 collection.

252 Lost follow-up is one of the major problems that affect the uptake of confirmatory HIV 253 testing.[14] The implementation of option B+ in Tanzania has remarkably increased the 254 uptake of confirmatory HIV testing at 18 months of age. However, most mothers are still 255 lost to follow-up after the first two months post-delivery. This study showed that 44% of 256 mothers brought their babies for confirmatory HIV testing at the 18<sup>th</sup> month, which is 257 higher than findings of past studies in Tanzania found only 34.6% of mothers brought their 258 babies to the test.[10, 15] Despite the fact that DBS-CPR 1 collection has been associated 259 with the increase in the uptake of confirmatory HIV testing; still more than 50% of mothers 260 who came for DBS-PCR 1 lost to follow up. The finding is consistent with findings of past 261 studies in Northern Tanzania, which revealed a high loss to follow-up after the first two 262 months post-delivery as one of the setbacks in the implementation of Option B+.[15, 16] 263 Does this have to do with insufficient knowledge about the Option B+ cascade of services 264 until after 18 months? Probably they thought that the DBS-PCR 1 test results were 265 confirmatory and there was no need for another test. Mothers of babies with HIV-negative 266 DBS-PCR 1 results need intensified counseling and close follow-up just like those who 267 test Positive. This will ensure that mother-baby pairs remain in treatment and babies remain 268 HIV-free until they graduate at 18 months.

269

270 Being an adult mother and experienced with PMTCT has been found to increase 271 compliance to Option B+. Adult mothers (aged 25 years and above) were more likely to 272 turn up for confirmatory HIV tests at their babies 18 months of age HIV than young 273 mothers (aged less than 25). The majority of the women in Tanzania have their first 274 delivery in their youth age.[17] Hence, by the time they reach adulthood age (25 years), 275 they have experienced reproductive health services and might have been exposed to 276 PMTCT services thus knowing the importance of adherence to services. Likewise, mothers 277 who were newly HIV diagnosed (less experienced with PMTCT) were less likely to turn 278 up for confirmatory HIV test at the 18-month post-delivery than mothers who knew their 279 HIV status before enrolment to antenatal care (experienced with PMTCT). Studies done in 280 sub-Saharan Africa have indicated poor adherence to Option B+ among young and newly 281 HIV-diagnosed mothers.<sup>3,4</sup>. Poor adherence among mothers enrolled in Option B+ has been 282 found to be associated with a lack of experience with PMTCT services, short time to 283 process and accept results, denial of the test results, fear of committing to a life-long 284 treatment regimen, feeling of shame, and stigma.[16, 18]

One of the unique findings in this study is that having a partner who has been tested for HIV is very important for compliance with Option B+ regardless of marital status. While marital status had no association with mothers turning in their babies for confirmatory HIV testing; mothers who had their partners tested for HIV are more likely to turn up for confirmatory HIV tests at their babies 18 months of age. This is contrary to recent studies in sub-Saharan Africa, which revealed that married mothers were more likely to adhere to option B+ than unmarried mothers. [19, 20]Awareness of the partner's HIV status has been

292 associated with compliance with Option B+ services. Studies in Malawi, Ethiopia, and 293 Kenya revealed that mothers who know the HIV status of their partners are more likely to 294 remain in Option B+ care than those who did not know[21]. The finding from this study 295 goes the extra mile as it indicates mothers who know that their partners have tested for HIV 296 regardless of knowledge of their HIV status have an impact on the compliance to Option 297 B+ care. Unfortunately, in this study, less than a quarter of mothers involved in the analysis 298 had their partners tested. The calls for more effort to educate male partners on the 299 importance of HIV testing.

300 The presence of treatment supporters improves mothers' compliance to Option B+ cascade 301 of services. The majority of mothers involved in this study had a treatment supporter. These 302 findings support studies showing that treatment supporters increase compliance with 303 Option B+.[16, 21-24] A treatment supporter can be a couple, a sibling, a relative, or a 304 friend who a mother has selected to assist. The use of treatment supporters has been a 305 successful technique used in patients with chronic conditions that require long-term course 306 treatment. For instance, treatment supporters have been useful for many years in Tanzania 307 to ensure patients' adherence to the tuberculosis treatment regime. [25, 26] The study 308 conducted Kilimanjaro region on the predictors of postpartum HIV care engagement 309 among women in the PMTCT program, suggested strengthening the social support network 310 system by engaging treatment supporters in HIV care. [13, 16, 18, 27, 28] Therefore, 311 findings from this study cement the importance of engaging treatment supporters not only 312 in engaging mothers to care but also to ensure that their babies receive the

## 313 Limitation

314 This study-employed data from the ministry of health management information system (HMIS) 315 and the PMTCT cascade survey data collected from 80 health facilities. The following limitations 316 were highlighted in this study: Data quality: only 751 of 4738 data collected were complete. This 317 might have affected or influenced some of the results. There is a need to train health workers on 318 the importance of proper documentation, constant supervision, and employ more health workers to 319 cover the shortage. Likewise, these findings are from the analysis of secondary data that were 320 primarily collected from the randomly selected health facilities for routine monitoring activities of 321 PMTCT services. Therefore, it is difficult to know exactly how well the data collection process 322 was done.

323

# 324 Conclusion

325 This study has found that the turn-up for confirmatory HIV testing at 18 months among 326 mother-baby pairs enrolled in the Option B+ approach is still low in Tanzania. More than 327 half of mothers lost to follow-up after the first two months post-delivery. This low turn-up 328 for the confirmatory HIV testing among mother-baby pairs enrolled in the Option B+ 329 approach is associated with low maternal age (young mothers), the low uptake of HIV 330 testing among male partners (having a male partner who has not tested for HIV), being a 331 newly diagnosed HIV mother (lack of experience to HIV services), lack of treatment supporters, and failure to take the first DBS-PCR HIV test within the first two months post-332 333 delivery. These factors have to be addressed in the Option B+ implementation guidelines 334 in order to increase the retention of mother-baby pairs into the Option+ B cascade of 335 services.

#### 336 **Recommendations for future directions**

The study recommends the following: Post-HIV testing counseling sessions among young mothers (mothers under 25 years of age) and newly HIV-diagnosed mothers be intensified; male partner involvement in reproductive services, couple counseling, and the importance of HIV result disclosure should be enhanced; and further studies be done to identify the best modalities of identifying, integrating and utilizing treatment supporters who will assist HIV infected mother to comply Option B+ cascade,

343

# 344 **Reference:**

UNAIDS U. Countdown to ZERO: global plan towards the elimination of new HIV
 infections among children by 2015 and keeping their mother alive: UNAIDS; 2011.

347 2. UNAIDS. 2015 progress report on the global plan towards the elimination of new
348 HIV infections among children and keeping their mothers alive. 2015.

349 3. Muyunda B, Musonda P, Mee P, Todd J, Michelo C. Effectiveness of lifelong ART
350 (Option B+) in the prevention of mother-to-child transmission of HIV programme in
351 Zambia: observations based on routinely collected health data. Frontiers in public health.
352 2020;7:401.

4. Kak L, Chitsike I, Luo C, Rollins N. Prevention of mother-to-child transmission of
HIV/AIDS programmes. Opportunities for Africa's newborns: Practical data, policy and
programmatic support for newborn care in Africa: WHO; 2011. p. 113-26.

356 5. AVERT. Prevention of mother-to-child transmisssion (PMTCT) of HIV 2017

357 [cited 2018]. Available from: <u>https://www.avert.org/professionals/hiv-</u>

358 programming/prevention/prevention-mother-child.

359 6. Gamell A, Luwanda LB, Kalinjuma AV, Samson L, Ntamatungiro AJ, Weisser M,

- 360 et al. Prevention of mother-to-child transmission of HIV Option B+ cascade in rural
- 361 Tanzania: The One Stop Clinic model. PloS one. 2017;12(7):e0181096.
- 362 7. MoHCDGEC. Tanzania Elimination of Mother to Child Transmission of HIV

363 Strategic Plan II 2018 – 2021. Da es Salaam: MoHCDGEC; 2017.

364 8. Kalua T, Tippett Barr B, van Oosterhout J, Mbori-Ngacha D, Schouten E, Gupta S,

365 et al. Lessons Learned From Option B+ in the Evolution Toward "Test and Start" From

366 Malawi, Cameroon, and the United Republic of Tanzania. Acquir Immune Defic Syndr.

367 2017;75(Suppl 1):S43-S50.

McLean E, Renju J, Wamoyi J, Bukenya D, Ddaaki W, Church K, et al. 'I wanted
to safeguard the baby': a qualitative study to understand the experiences of Option B+ for
pregnant women and the potential implications for 'test-and-treat' in four sub-Saharan
African settings. Sex Transm Infect. 2017;93(Suppl 3).

372 10. Samson S, Mpembeni RN, Njau PF, Kishimba RS. Uptake of early infant diagnosis

373 (EID) at six weeks after cessation of breastfeeding among HIV exposed children: A cross
374 sectional survey at six high volume health facilities in Iringa, Tanzania. Journal of
375 Interventional Epidemiology and Public Health. 2018;1(10).

376 11. MoHSW T. National Guidelines for Comprehensive Care Services for Prevention
377 of Mother-to-Child Transmission of HIV and Keeping Mothers Alive. In: Programme NP,

- ditor. Dar es Salaam, Tanzania: MoHSW, Tanzania; 2013.
- 379 12. UNAIDS. 2015 PROGRESS REPORT ON THE GLOBAL PLAN
- towards the elimination of new HIV infections among children and keeping their mothers
- alive. 2015.

Atanga P. Retention-in-Care, Adherence and Treatment outcomes in a cohort of 382 13. 383 HIV- positive pregnant and breastfeeding women enrolled in a pilot project implementing 384 "Option B+" in Cameroon.: Medical Centre of the University of Munich (LMU); 2016. 385 14. Gumede-Moyo S, Filteau S, Munthali T, Todd J, Musonda P. Implementation 386 effectiveness of revised (post-2010) World Health Organization guidelines on prevention 387 of mother-to-child transmission of HIV using routinely collected data in sub-Saharan 388 Africa: a systematic literature review. Medicine. 2017;96(40). 389 Cichowitz C, Mazuguni F, Minja L, Njau P, Antelman G, Ngocho J, et al. 15. 390 Vulnerable at each step in the PMTCT care cascade: high loss to follow up during 391 pregnancy and the postpartum period in Tanzania. AIDS and Behavior. 2019;23(7):1824-

392 32.

Mazuguni F, Mwaikugile B, Cichowitz C, Watt MH, Mwanamsangu A, Mmbaga
BT, et al. Unpacking loss to follow-up among HIV-infected women initiated on option B+
in Northern Tanzania: a retrospective chart review. EA Health Research Journal.
2019;3(1):6-15.

397 17. Ministry of Health CD G, Elderly, Children MoHMZ NBoS. Tanzania
398 demographic and health survey and malaria indicator survey (TDHS-MIS) 2015–16.
399 MoHCDGEC, MoH, NBS, OCGS, and ICF Dar es Salaam, Tanzania, and Rockville,
400 Maryland, USA. 2016.

401 18. Watt MH, Cichowitz C, Kisigo G, Minja L, Knettel BA, Knippler ET, et al. 402 Predictors of postpartum HIV care engagement for women enrolled in prevention of 403 mother-to-child transmission (PMTCT) programs in Tanzania. AIDS care. 404 2019;31(6):687-98.

405 19. Lencha M. Adherence to option B+ and associated factors among pregnant women
406 on PMTCT Services at Public Health Facilities of east Shawa zone, Oromia, Ethiopia. J
407 Womens Health Reprod Med. 2018;2(1):2.

408 20. Flax VL, Hamela G, Mofolo I, Hosseinipour MC, Hoffman IF, Maman S. Factors

409 influencing postnatal Option B+ participation and breastfeeding duration among HIV-

410 positive women in Lilongwe District, Malawi: A qualitative study. PloS one.
411 2017;12(4):e0175590.

412 21. Asefa EY, Dirirsa DE. Level of Good Adherence on Option B+ PMTCT and

413 Associated Factors Among HIV Positive Pregnant and Lactating Mothers in Public Health

414 Facilities of Ilu Abba Bor and Buno Bedele Zones, Oromia Regional State, Southwestern

415 Ethiopia, 2018. HIV/AIDS (Auckland, NZ). 2020;12:789.

416 22. Yeshialem Asefa E, Edosa Dirirsa D. Level of Good Adherence on Option B+

417 PMTCT and Associated Factors Among HIV Positive Pregnant and Lactating Mothers in

418 Public Health Facilities of Ilu Abba Bor and Buno Bedele Zones, Oromia Regional State,

419 Southwestern Ethiopia, 2018. HIV AIDS (Auckl). 2020;12:789-98. doi:

420 10.2147/HIV.S283184. PubMed PMID: 33273864.

421 23. Wondimu F, Yetwale F, Admassu E, Binu W, Bulto GA, Lake G, et al. Adherence

422 to Option B+ Care for the Prevention of Mother-to-Child Transmission Among Pregnant

423 Women in Ethiopia. HIV/AIDS (Auckland, NZ). 2020;12:769.

424 24. Kisigo GA, Ngocho JS, Knettel BA, Oshosen M, Mmbaga BT, Watt MH. "At

425 home, no one knows": A qualitative study of retention challenges among women living

426 with HIV in Tanzania. Plos one. 2020;15(8):e0238232.

427	25	Mkopi A Ra	ange N Lwill	a F Egwa	ga S Schulze A	Geubbels E	et al. Adherence

- 428 to tuberculosis therapy among patients receiving home-based directly observed treatment:
- 429 evidence from the United Republic of Tanzania. PloS one. 2012;7(12):e51828.

430 26. Mkopi A, Range N, Amuri M, Geubbels E, Lwilla F, Egwaga S, et al. Health

- 431 workers' performance in the implementation of Patient Centred Tuberculosis Treatment
- 432 (PCT) strategy under programmatic conditions in Tanzania: a cross-sectional study. BMC
- 433 health services research. 2013;13(1):1-7.

434 27. Atanga PN. Retention-in-care, adherence and treatment outcomes in a cohort of

- 435 HIVpositive pregnant and breastfeeding women enrolled in a pilot project implementing
- 436 "Option B+" in Cameroon: Imu; 2017.
- 437 28. Atanga PN, Ndetan HT, Achidi EA, Meriki HD, Hoelscher M, Kroidl A. Retention
- 438 in care and reasons for discontinuation of lifelong antiretroviral therapy in a cohort of
- 439 Cameroonian pregnant and breastfeeding HIV-positive women initiating 'Option B+'in the
- 440 South West Region. Tropical Medicine & International Health. 2017;22(2):161-70.

441

442